Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Sam Samad Biography and Net Worth

CFO of Illumina

Sam Samad joined Illumina in 2017 and holds the role of Chief Financial Officer with responsibility for the company’s finance, accounting, investor relations, internal audit, treasury, and global information systems functions.

Before joining Illumina, Samad held several senior leadership positions at Cardinal Health including Senior Vice President and Corporate Treasurer, leading all tax and treasury functions. During his tenure as Treasurer, Samad also had operational and financial responsibility for Cardinal Health’s China business. Prior to that, Samad served as Senior Vice President and Chief Financial Officer for Cardinal Health’s $85B pharmaceutical segment, among other leadership roles. Prior to Cardinal Health, Samad spent thirteen years at Eli Lilly and Company, in a variety of sales and finance roles, both domestically and internationally, including his role as Chief Financial Officer of the Canada affiliate prior to leaving Eli Lilly. Samad started his career at Pepsico Inc.

Samad has served as Director on the Board for IDEXX Laboratories, Inc. (IDXX) since July 2019 and on the Board of Visitors at the Owen Graduate School of Management since 2016.

Samad holds a BBA degree from the American University of Beirut in Lebanon and an MBA from McMaster University in Hamilton, Canada.

What is Sam Samad's net worth?: The estimated net worth of Sam Samad is at least $469,552.95 as of May 26th, 2020. Mr. Samad owns 3,879 shares of Illumina stock worth more than $469,553 as of April 25th. This net worth evaluation does not reflect any other assets that Mr. Samad may own. Learn More about Sam Samad's net worth.
How do I contact Sam Samad?: The corporate mailing address for Mr. Samad and other Illumina executives is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. Illumina can also be reached via phone at (858) 202-4500 and via email at [email protected]. Learn More on Sam Samad's contact information.
Has Sam Samad been buying or selling shares of Illumina?: Sam Samad has not been actively trading shares of Illumina during the past quarter. Most recently, Sam Samad sold 1,356 shares of the business's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $360.00, for a transaction totalling $488,160.00. Following the completion of the sale, the chief financial officer now directly owns 3,879 shares of the company's stock, valued at $1,396,440. Learn More on Sam Samad's trading history.
Who are Illumina's active insiders?: Illumina's insider roster includes Alexander Aravanis (SVP), Frances Arnold (Director), Charles Dadswell (SVP), Francis deSouza (CEO), Phillip Febbo (SVP), Jay Flatley (Director), Aimee Hoyt (SVP), Karen Mcginnis (CAO), Robert Ragusa (SVP), Mostafa Ronaghi (SVP), Sam Samad (CFO), Susan Tousi (SVP), and Mark Van Oene (SVP). Learn More on Illumina's active insiders.
Are insiders buying or selling shares of Illumina?: In the last year, Illumina insiders bought shares 1 times. They purchased a total of 7,330 shares worth more than $991,675.70. In the last year, insiders at the life sciences company sold shares 4 times. They sold a total of 1,815 shares worth more than $314,104.60. The most recent insider tranaction occured on February, 22nd when CEO Jacob Thaysen bought 7,330 shares worth more than $991,675.70. Insiders at Illumina own 0.2% of the company. Learn More about insider trades at Illumina.
Information on this page was last updated on 2/22/2024.

Sam Samad Insider Trading History at Illumina

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/26/2020	Sell	1,356	$360.00	$488,160.00	3,879
5/18/2020	Sell	1,357	$340.00	$461,380.00	5,235
4/20/2020	Sell	1,356	$320.02	$433,947.12	6,592
4/16/2020	Sell	1,697	$300.00	$509,100.00	7,948
4/14/2020	Sell	249	$292.54	$72,842.46	9,645
11/29/2019	Sell	892	$320.00	$285,440.00	3,461

Sam Samad Buying and Selling Activity at Illumina

Illumina Company Overview

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Today's Range

Now: $121.05

$116.91

$121.97

50 Day Range

MA: $131.94

$116.69

$143.41

2 Week Range

Now: $121.05

$89.00

$217.60

Volume

962,067 shs

Average Volume

1,729,586 shs

Market Capitalization

$19.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19